These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27550304)

  • 1. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Lunt M; Low AL; Dixon WG; Watson KD; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2015 Jun; 74(6):1087-93. PubMed ID: 24685910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy.
    Xie W; Xiao S; Huang Y; Sun X; Gao D; Ji L; Li G; Zhang Z
    Rheumatology (Oxford); 2020 May; 59(5):930-939. PubMed ID: 31620795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
    Low AS; Symmons DP; Lunt M; Mercer LK; Gale CP; Watson KD; Dixon WG; Hyrich KL;
    Ann Rheum Dis; 2017 Apr; 76(4):654-660. PubMed ID: 28073800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
    Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
    Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bechman K; Halai K; Yates M; Norton S; Cope AP; ; Hyrich KL; Galloway JB
    Arthritis Rheumatol; 2021 Oct; 73(10):1800-1809. PubMed ID: 33844458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK; Galloway JB; Lunt M; Davies R; Low AL; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL
    Ann Rheum Dis; 2017 Mar; 76(3):497-503. PubMed ID: 27502891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence.
    Singh N; Li CI
    Curr Opin Rheumatol; 2021 May; 33(3):292-299. PubMed ID: 33741804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
    Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
    Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.
    Strangfeld A; Hierse F; Rau R; Burmester GR; Krummel-Lorenz B; Demary W; Listing J; Zink A
    Arthritis Res Ther; 2010; 12(1):R5. PubMed ID: 20064207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
    Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
    Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.
    Wadström H; Frisell T; Sparén P; Askling J;
    Ann Rheum Dis; 2016 Jul; 75(7):1272-8. PubMed ID: 26755797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.
    Fagerli KM; Kearsley-Fleet L; Mercer LK; Watson K; Packham J; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2019 Jan; 58(1):80-85. PubMed ID: 30137485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data.
    Jung SM; Kwok SK; Ju JH; Park YB; Park SH
    Korean J Intern Med; 2019 May; 34(3):669-677. PubMed ID: 29172405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.